MYDA Advisors’s Gain Therapeutics GANX Stock Holding History

MYDA Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,000	Closed	-$209K	–	300
2021 Q1	$209K	Buy	+14,000	New	+$184K	0.06%	246

Other funds holding GANX

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $2.66B AUM 26.89% 1-Year Est. Return

MYDA Advisors's GANX Position: Q2 2021 in Review

MYDA Advisors sold out of Gain Therapeutics (GANX) in Q2 2021, closing a stake of 14,000 shares — an estimated $209K sold.

MYDA Advisors first reported a position in GANX in Q1 2021 and held it in 1 quarter. The position peaked at $209K in Q1 2021. 14 funds tracked by Wall St. Rank hold GANX as of Q2 2021.

MYDA Advisors reported no remaining Gain Therapeutics position as of Q2 2021 after selling out during the quarter.
MYDA Advisors sold 14,000 Gain Therapeutics shares in Q2 2021, an estimated $209K.
MYDA Advisors first reported a position in Gain Therapeutics in Q1 2021 and held it in 1 quarter.
MYDA Advisors's Gain Therapeutics position peaked at $209K in Q1 2021.
14 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2021.

Based on MYDA Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.